Overview

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.
Phase:
Phase 3
Details
Lead Sponsor:
Health Ever Bio-Tech Co., Ltd.